Slingshot members are tracking this event:

Regeneron's (REGN) Evinacumab Designated Breakthrough Therapy for Hypercholesterolemia in Patients with Homozygous Familial Hypercholesterolemia (HoFH)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 06, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Evinacumab, Breakthrough Therapy, Fda, Hypercholesterolemia, Homozygous Familial Hypercholesterolemia